A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model
{{output}}
Aim: Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (PD-1) therapy, have improved cancer treatment outcomes, yet durable benefit is achieved in only a subset of patients. Growing evidence implicates the gut microbiome as... ...
